United-Guardian, Inc.

What they do

United-Guardian, Inc. is a Delaware corporation operating through its Guardian Laboratories division. It manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, along with a line of healthcare products including pharmaceuticals and medical lubricants. Its Lubrajel line of multifunctional hydrogel formulations is described as one of its most important product lines, and its most important pharmaceutical product is Renacidin. All products except Renacidin are produced at its Hauppauge, New York facility; Renacidin is made by an outside contract manufacturer.

Revenue drivers

• Cosmetic ingredients (Lubrajel line) — Marketed worldwide through distributors and used by major cosmetic manufacturers; the Lubrajel line of multifunctional hydrogel formulations is one of the most important product lines, and cosmetic ingredient sales include a COSMOS-certified natural line. Cosmetic ingredient sales rose 44% in Q2 2026 and 34% in the first half of 2026 versus the prior-year periods.
• Pharmaceuticals (Renacidin and Clorpactin WCS-90) — Renacidin is described as the most important pharmaceutical product; sales carry fees, rebates and allowances that distinguish gross from net sales. Pharmaceutical sales increased 1% in Q2 2026 and 11% in the first half of 2026 versus the prior-year periods.
• Medical lubricants — Included in the healthcare products line alongside pharmaceuticals; growing the medical lubricant business is named as one of management's growth plan priorities.
• Sexual wellness ingredients (Natrajel line) — A new line covered by a January 2026 distribution agreement with Brenntag Specialties for the United States, Canada, Mexico and, for Lubrajel and Natrajel, France. There were no sexual wellness sales in 2025; the company reported a nominal amount of sales in Q2 2026.

Recent performance

Second quarter 2026 net sales rose 10% to $3,108,267 from $2,838,225 in the prior-year period, and net income rose 16% to $728,579 ($0.16 per share) from $626,826 ($0.14 per share). For the six months ended June 30, 2026, net sales rose 12% to $5,980,489 from $5,319,352, and net income rose 30% to $1,547,481 ($0.34 per share) from $1,187,721 ($0.26 per share). First-half 2026 other income totaled $554,169, including $339,493 of settlement income. Full-year results show the longer trend: revenue declined from $13.9M in 2021 to $10.5M in 2025, with net income of $2.1M and diluted EPS of $0.46 in 2025.

Strategy

In January 2026 the company entered a new distribution agreement with Brenntag Specialties covering the new Natrajel sexual wellness line in the United States, Canada and Mexico and Lubrajel and Natrajel in France. In 2025 it launched an insurance payer outreach program for Renacidin; two major Pharmacy Benefit Managers approved formulary inclusion beginning in 2026, effective June 1 and July 1, 2026. Management states its 2026 growth plan includes expanding promotional efforts and awareness for Renacidin among physicians and care providers, increasing awareness of its natural products, and growing the medical lubricant business. The company develops products using natural and environmentally friendly raw materials and typically protects proprietary technology as trade secrets rather than patents.

Risks

• Trade policy and tariffs — The 10-K states that 2025 changes in U.S. trade policy and retaliatory tariffs could disrupt material sourcing, supply chains, logistics and end-market access and negatively affect results, with no assurance new tariffs will not be imposed.
• Customer concentration — The 10-Q attributes the Q2 2026 cosmetic ingredient sales increase primarily to increased purchases by Ashland Specialty Ingredients, described as the largest cosmetic distributor, after it reduced higher-than-normal 2025 inventory levels.
• New sexual wellness line has minimal revenue — The company reported no sexual wellness sales in 2025 and only a nominal amount in Q2 2026, so the Natrajel line has not yet contributed meaningful revenue.
• Single-site manufacturing and contract dependence — All products except Renacidin are produced at the Hauppauge, New York facility, and Renacidin is manufactured by an outside contract manufacturer.

Outlook

Management says it is optimistic about the potential of the sexual wellness market and expects that segment to grow at a higher compound annual growth rate than skin care, personal care and cosmetics. In 2026 it will continue insurance payer outreach for Renacidin while introducing a new program to increase awareness among healthcare professionals. The company states it is focused on expanding promotional efforts, increasing awareness of its natural products, and growing its medical lubricant business.